St. Jude Medical Inc. announced U.S. Food and Drug Administration (FDA) approval of the FlexAbility Ablation Catheter, a new ablation technology used by electrophysiologists for the treatment of cardiac arrhythmias.

The silence is deafening. And since radiology associations, physician groups and vendors have yet to publicly respond to the elephant in the room, I offer the following in hopes we can get the conversation started...

The Diagnostics Division of Siemens Healthcare unveiled its latest point-of-care acute care analyzer for the management of patients with cardiovascular disease symptoms at Medlab in Arab Health 2015, Dubai, Jan. 26-29. The company’s Stratus CS 200 Acute Care Diagnostic System is designed to enhance simple operation and instrument management at the point of care to help facilitate rapid decision-making and optimal patient care.

A tool designed to assess what interferes with acute heart failure patients' ability to care for themselves after hospital discharge holds promise for improving patient outcomes and reducing readmissions to the hospital. The patient survey, designed by researchers at Vanderbilt University, was published online in Annals of Emergency Medicine, along with patient responses that shed light on the non-medical issues that limit patients' ability to care for themselves.

Neovasc Inc. has commenced a public offering in the United States of 8 million shares of the company to raise money for upcoming U.S. clinical trials and development of its transcatheter mitral valve and treatment system for refractory angina.

Maquet Medical Systems USA announced an agreement to serve as the exclusive U.S. distributor of InterValve Inc.'s V8 Aortic Valvuloplasty Balloon Catheter.

Abiomed impella, Impella RP, Impella right percutaneous

Abiomed Inc. said the Impella RP (Right Percutaneous) system has received U.S. Food and Drug Administration (FDA) approval under a humanitarian device exemption (HDE). This is the first percutaneous single access heart pump designed for right heart support to receive FDA approval. Abiomed completed the HDE submission for the Impella RP in September 2014 following the completion of the RECOVER RIGHT study.
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now